Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (101-110 of 198) with videos related to

Pageof 20
Sort By:
Arthritis Research & Therapy|March 17, 2018
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)Peter Nash, Philip J Mease, Iain B McInnes, et al.
RMD Open|November 19, 2021
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritisEffie Pournara, Matthias Kormaksson, Peter Nash, et al.
Journal of Visualized Experiments : Jove|October 22, 2016
Nutrient Regulation by Continuous Feeding for Large-scale Expansion of Mammalian Cells in SpheroidsBradley P Weegman, Ahmad Essawy, Peter Nash, et al.
The Journal of Rheumatology|December 1, 2025
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With GuselkumabWilliam Tillett, Laura C Coates, Marijn Vis, et al.
Rheumatology (Oxford, England)|January 13, 2024
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysisPhilip J Mease, Dafna D Gladman, Joseph F Merola, et al.
Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
Seminars in Arthritis and Rheumatism|December 8, 2022
Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studiesEmilce E Schneeberger, Gustavo Citera, Peter Nash, et al.
The Journal of Rheumatology|November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III StudiesChristina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
Arthritis and Rheumatism|April 3, 2008
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyJonathan Kay, Eric L Matteson, Bhaskar Dasgupta, et al.
Arthritis Research & Therapy|October 31, 2018
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of diseasePhilip Helliwell, Laura C Coates, Oliver FitzGerald, et al.
Pageof 20

Showing results (101-110 of 198) with videos related to

Sort By:
Pageof 20
Arthritis Research & Therapy|March 17, 2018
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)Peter Nash, Philip J Mease, Iain B McInnes, et al.
RMD Open|November 19, 2021
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritisEffie Pournara, Matthias Kormaksson, Peter Nash, et al.
Journal of Visualized Experiments : Jove|October 22, 2016
Nutrient Regulation by Continuous Feeding for Large-scale Expansion of Mammalian Cells in SpheroidsBradley P Weegman, Ahmad Essawy, Peter Nash, et al.
The Journal of Rheumatology|December 1, 2025
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With GuselkumabWilliam Tillett, Laura C Coates, Marijn Vis, et al.
Rheumatology (Oxford, England)|January 13, 2024
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysisPhilip J Mease, Dafna D Gladman, Joseph F Merola, et al.
Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
Seminars in Arthritis and Rheumatism|December 8, 2022
Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studiesEmilce E Schneeberger, Gustavo Citera, Peter Nash, et al.
The Journal of Rheumatology|November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III StudiesChristina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
Arthritis and Rheumatism|April 3, 2008
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyJonathan Kay, Eric L Matteson, Bhaskar Dasgupta, et al.
Arthritis Research & Therapy|October 31, 2018
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of diseasePhilip Helliwell, Laura C Coates, Oliver FitzGerald, et al.
Pageof 20